The Medical Letter on Drugs and Therapeutics
Vismodegib (Erivedge) for Basal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma that has recurred after surgery, or locally advanced basal cell carcinoma in adults who are not candidates for surgery or radiation.

MECHANISM OF ACTION — The Hh signaling pathway, which is important in embryonic development and regulation of adult stem cells, has been implicated in the development of several human cancers.1 Mutations in the Hh pathway are thought to be the cause of basal cell carcinoma.2 Vismodegib inhibits the signaling activity of a transmembrane protein in this pathway. It has shown activity against lung and pancreatic cancer cells in vitro and hepatocellular carcinoma in mice, in addition to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vismodegib (Erivedge) for Basal Cell Carcinoma
Article code: 1394a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian